Aptevo Therapeutics

Company snapshot

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platfo

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 13 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Aptevo Therapeutics. Not investment advice.

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 28

• Peer + 0 momentum

  Genmab

  TA overlap score 25.8

• Peer + 0 momentum

  Astellas Pharma

  TA overlap score 24.4

• Peer + 0 momentum

  IO Biotech

  TA overlap score 23.2

• Peer + 0 momentum

  Zentalis Pharmaceuticals

  TA overlap score 22.8

Recent activity

Latest pipeline, patent, and corporate events for Aptevo Therapeutics.

1. Jun 8, 2026 Clinical update

   APVO436 — Phase 1

2. Jun 5, 2026 Clinical update

   TRU-016 (anti-CD37 protein therapeutic) — Phase 1

3. Jun 5, 2026 Clinical update

   TRU-016 and bendamustine — Phase 2

4. May 23, 2026 Clinical update

   ALG.APV-527 — Phase 2

5. May 23, 2026 Clinical update

   20 mg/kg TRU-016 + Rituximab — Phase 1

View all clinical trial activity →

• What is Aptevo Therapeutics?

  Aptevo Therapeutics is a pharma organization headquartered in Seattle, USA. It trades on NYSE under ticker APVO. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia (CLL), Chronic Lymphocytic Leukemia, Solid Tumor, Psoriasis, Acute Myeloid Leukemia (AML). NovaPha

• Is Aptevo Therapeutics publicly traded?

  Yes. Aptevo Therapeutics is listed with ticker APVO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Aptevo Therapeutics develop or market?

  We link 4 drug profile(s) where Aptevo Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aptevo-therapeutics#company-drugs.

• What are the latest developments for Aptevo Therapeutics?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Aptevo Therapeutics focus on?

  Aptevo Therapeutics focuses on Chronic Lymphocytic Leukemia (CLL), Chronic Lymphocytic Leukemia, Solid Tumor based on our analysis of their pipeline programs and drug development activities.